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The latest technical improvements in the surgical armamentarium are remarkable. 
In particular, advancements in the urologic field are so exceptional that we could ob-
serve the flare-up of robot-assisted laparoscopic radical prostatectomy for prostate can-
cer and laser prostatectomy for benign prostatic hyperplasia (BPH). Photoselective va-
porization of the prostate (PVP) and holmium laser prostatectomy are the most general-
ized options for laser surgery of BPH, and both modalities have shown good post-
operative results. In comparison to transurethral prostatectomy (TURP), they showed 
similar efficacy and a much lower complication rate in randomized prospective clinical 
trials. Even in cases of large prostates, laser prostatectomy showed comparable efficacy 
and safety profiles compared to open prostatectomy. From a technical point of view, 
PVP is considered to be an easier technique for the urologist to master. Furthermore, 
patients can be safely followed up in an outpatient clinic. Holmium laser enucleation 
of the prostate (HoLEP) mimics open prostatectomy because the adenomatous tissue 
is peeled off the surgical capsule in both procedures. Therefore, HoLEP shows notable 
volume reduction of the prostate similar to open prostatectomy with fewer blood trans-
fusions, shorter hospital stay, and cost reduction regardless of prostate size. Outcomes 
of laser prostatectomy for BPH are encouraging but sometimes are unbalanced because 
safety and feasibility studies were reported mainly for PVP, whereas long-term data 
are mostly available for HoLEP. We need longer-term randomized clinical data to iden-
tify the reoperation rate of PVP and to determine which procedure is the ideal alter-
native to TURP and open prostatectomy for each patient. 
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INTRODUCTION
Technological improvements in modern medical science 
help us to treat patients much easier than before, as we 
have witnessed throughout the history of medicine. This 
is equally applicable to the surgical treatment of benign 
prostatic hyperplasia (BPH). The goal of the surgical man-
agement of BPH is to reduce the bulk of the prostate to re-
lieve the obstruction of the urinary tract due to the enlarged 
prostate. The classical treatment is open prostatectomy or 
transurethral prostatectomy (TURP). Open prostatec-
tomy is an invasive procedure, associated with significant 
morbidity, and requires a lower abdominal incision, with 
consequently longer hospitalization and recovery periods. 
Although TURP remains an effective treatment, 15% to 
20% of patients develop significant complications, and 10% 
to 15% require a second intervention within 10 years [1]. 
To improve safety outcomes, a number of minimally in-
vasive surgical techniques have been developed, such as 
needle ablation, electrovaporization, vaporization resection, 
holmium laser, ultrasound, and microwave therapy. These 
alternative surgical treatments have shown favorable out-
comes to date [2,3]. Each laser used for prostatectomy has 
its unique wavelength and tissue interaction character-
istic that make each wavelength act differently when ap-
plied to prostatic tissue [3]. In this article, we review the 
safety, efficacy, and durability of the various current laser 
treatments for BPH. Korean J Urol 2010;51:737-744
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PHOTOSELECTIVE VAPORIZATION OF THE 
PROSTATE (PVP)
1. General aspects of PVP 
With a potassium titanyl phosphate (KTP) crystal, the fre-
quency of pulsed neodymium:yttrium aluminium garnet 
(Nd:YAG) laser energy is doubled and made a 532 nm 
wavelength. Because the KTP laser is strongly absorbed by 
hemoglobin and minimally absorbed in water, the KTP la-
ser effectively enables vaporization rather than coagu-
lation of prostatic tissue and has excellent hemostasis abil-
ity [2,4]. 
　In 1998, Malek et al reported the first clinical trial with 
a 60 W KTP laser [5]. Later, the GreenLight company im-
proved the power of the 520 nm laser up to 80 W KTP and 
120 W high-performance system (HPS) with lithium tribo-
rate (LBO), which have led several urologists to use these 
new instruments for BPH treatment [4,6-9]. PVP is consid-
ered to be an easier technique for the urologist to master, 
and the operator can create a similar postoperative pro-
static fossa resembling that of TURP [10,11]. However, no 
study to date has correctly assessed the learning curve for 
PVP in Korea [6,12-15]. 
　The indication for PVP is almost the same as with TURP. 
With the use of the 80 W KTP laser instrument, prostates 
larger than 80 ml can be effectively treated [6,16,17]. As the 
120 W HPS laser entered the urologic stage, treatment of 
large prostates became easier than before [6]. PVP can be 
used in patients with a high risk of treatment-related com-
plications, in elderly aged 80 years or older, and even in an-
ticoagulant users [6,18-20]. 
2. Surgical technique 
　1) Vaporization technique: Usually PVP can be per-
formed in a smaller diameter cystoscopic sheath such as a 
21 Fr than that of TURP. If possible, a video monitor needs 
to be placed right in front of the surgeon. The camera unit 
has to be protected from the laser light by a specific filter. 
The GreenLight laser has a green color as the name implies. 
Without the filter, the video monitor will be filled with 
green color whenever the laser firing is on. Normal saline 
is recommended as the irrigating fluid and can be drained 
continuously through the drainage system. After the cysto-
scopic instrument is inserted, the operator should check 
the intravesical environment and the position of the ure-
teral orifices. Laser firing should be under the guidance of 
the red guiding light. Vaporization can be started at the 6 
o’clock position of the bladder neck or at one of the two later-
al lobes of the prostate. Effective lasing makes many air 
bubbles in the cystoscopic field of vision. During vapor-
ization, the position of the trigone, bladder neck, and ure-
teral orifices should be imprinted in the surgeon’s mind for 
protection from unwanted damage. After making suffi-
cient space in the prostatic fossa mimicking TURP, a Foley 
catheter needs to be placed for several to 24 hours before 
a voiding trial [21].
　2) Vaporesection technique with GreenLight HPS (Seoul 
technique):  There are several limitations to the PVP 
technique. The PVP results in a bumpy surface of the pros-
tate following vaporization, and pathologic evaluation of 
prostate tissue is not feasible. Also, it takes more laser fi-
bers and a longer operative time for a larger prostate. The 
Seoul technique includes a planned vaporization-resection, 
not vaporization only. This technique involves vaporization 
of the prostate along the previously outlined margins and 
retrieval of the resulting wedge-shaped prostatic tissue 
[22]. The operation consists of the following 3 steps. First, 
the vaporization-resection of the median lobe is performed. 
One should dig into the prostate while vaporizing along the 
lateral margins of the median lobe. The proximal margin 
is the bladder neck, and the distal margin is the level of the 
verumontanum. Secondly, the vaporization-resection of 
both lateral lobes follows. Before the resection of the lateral 
lobes, 2 semicircular lines are placed on the distal part of 
both lateral lobes at the level of the verumontanum, the dis-
tal margin of the TUR-like cavity, maintaining a constant 
depth. The S-point is a concave point near the bladder neck 
made by the protruding lateral lobe and the roof of the pro-
static urethra, the starting point for the resection of the lat-
eral lobe. Finally, the operator must flatten the rough sur-
face and make a complete cavity by additional vaporization. 
At the end of the procedure, one can remove the prostatic 
tissue by using the foreign body forceps. Son et al reported 
favorable results regarding improvement of voiding symp-
toms and urinary flow rate, with a very low complication 
rate [22].
3. Results
　1) Short-term results: Araki et al prospectively eval-
uated 160 patients who underwent 80 W KTP-PVP [23]. 
After a maximum follow-up of 52 weeks, the mean Interna-
tional Prostate Symptom Score (IPSS) decreased signifi-
cantly from 23 to 13, and the maximum urinary flow rate 
(Qmax) and postvoiding residual urine volume (PVR) also 
improved significantly (Table 1). Reich et al performed 80 
W KTP-PVP on 66 patients with high cardiopulmonary 
risk (ASA score ＞=3) [20]. After a maximum follow-up of 
12 months, there were no major complications. Also, the 
Qmax and IPSS score improved significantly. Among these 
66 patients, 29 were taking anticoagulants. A multicenter 
prospective trial for KTP-PVP was reported by Te et al in 
2004 [24]. This prospective clinical trial with 139 men 
showed statistically significant improvements in IPSS, 
quality of life (QoL) score, Qmax, and PVR after 12 months. 
The prostate volume measured by transrectal ultrasound 
was 54.6 ml at baseline and changed to 34.4 ml at 12 
months. With direct comparison of traditional TURP and 
KTP-PVP, good clinical improvement was also achieved. In 
a retrospective study including 396 patients (KTP-PVP 
269, TURP 127), Ruszat et al reported a lower complication 
rate and similar clinical efficacy except for Qmax in the 
KTP-PVP group [25]. Tugcu et al also compared TURP 
(n=98) and 80 W KTP-PVP (n=112) [26]. After 2 years of 
follow-up, both groups showed significant improvement of Korean J Urol 2010;51:737-744
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TABLE 1. Short-term and long-term results of photoselective vaporization of the prostate
Ref.
No. of 
cases
Mean age
(yr)
F/U
Mean
P vol.
QoL
score
Qmax PVR IPSS
Short-term
Long-term
20
23
24
25
26
27
31
32
  66
160
139
269
  98
  70
  68
321
   75 (54-95)
69.7 (34-88)
67.7±8.7
72±9.7
67.5±7.4
   67 (45-87)
68±8
(-)
1 yr
1 yr
1 yr
2 yr
2 yr
1 yr
5 yr
5 yr
Pre-op
Post-op
Pre-op
Post-op
Pre-op
Post-op
Pre-op
Post-op
Pre-op
Post-op
Pre-op
Post-op
Pre-op
Post-op
Pre-op
Post-op
49±30
-
72.3 (20.3-261)
-
54.6±31.7
34.4±14.1
64.8±26.8
37.8
49.1±11.9
-
61.6 (20.9-263.0)
30.4
45±17
-
54.7±29.9
42.7±22.5
-
-
4.5 (1-6)
0.8 (0-3)
4.3±1
1.0±1.5
-
-
3.4±0.6
1.1±0.4
   4 (4-5)
0
4.5±1.2
0.1±0.4
4.2±0.9
0.8±0.8
6.7±2
21.6±7
10.9 (0.6-34.9)
22.0 (7.7-46.6)
7.8±3.8
22.6±7.6
7.3±2.7
-
6.9±1.9
16.8±1.6
9.4 (6.7-12.0)
20.0 (18.2-24.9)
7.8±2.3
22.2±9.0
8.6±3.5
21.1±6.3
147±130
25±31
109 (0-691)
  32 (0-175)
114.3±122
24.8±44.1
-
-
107.9±63.0
7.5±2.7
19 (0-75)
  4 (0-53)
197±143
25±26
169.9±228.8
27.9±56.6
20.2±6
6.5±4
22.8 (6-35)
  5.9 (0-21)
 24±5.9
4.3±5.8
18.6±5.8
-
17.9±4.9
3.1±0.9
  22 (18-26)
4 (3-5)
22±6
2.6±1.6
 24±5.3
5.0±3.0
Ref.: reference number, F/U: follow-up period, Mean P vol.: mean prostate volume, QoL: quality of life, Qmax: maximum urinary flow
rate, PVR: post void residual, IPSS: International Prostate Symptom Score, Pre-op: preoperation, Post-op: postoperation
the voiding profile; however, the catheter indwelling peri-
od and hospital stay were shorter in the KTP-PVP group. 
In another 6-month retrospective report of HPS-PVP, 
Spaiviero et al reported significant improvement in the 
IPSS and Qmax in 70 patients [27]. From a series of studies 
on KTP-PVP in Korea, Kim et al and Ku et al and Lee et 
al showed that the 80 W KTP-PVP is safe and efficacious 
for up to 24 months of follow-up, regardless of prostate vol-
ume, although a larger prostate requires more time and en-
ergy delivery [28-30]. The complication rate was also lower 
and there was no de novo erectile dysfunction.
　2) Long-term results: Malek et al reported on results with 
a 5-year follow-up period in 2005 [31]. They reported ex-
cellent clinical outcomes and the symptomatic and urody-
namic improvements were sustained with a minimum ne-
cessity for re-intervention. Complications were transient 
dysuria (6%), delayed hematuria (3%), bladder neck con-
tracture (2%), and retention (1%). Hai evaluated the 5-year 
clinical outcomes and durability of KTP-PVP with avail-
able follow-up for 246 of the 321 patients and reported im-
provement in the IPSS (79%), QoL score (80%), Qmax 
(172%), TRUS (17%), and PVR (77%) [32].
　3) Complications: According to the prospective trial re-
ported by Te et al, there was no significant blood loss or fluid 
absorption during or immediately after PVP after 1 year 
of follow-up [24]. Complications consisted of transient 
hematuria, dysuria, and urinary retention in 12 (8.6%), 13 
(9.3%), and 7 (5%) patients, respectively. Spaliviero et al 
reported that perioperative complications after HPS-PVP 
included intraoperative bleeding (1.4%), postoperative 
clinically nonsignificant hematuria (78.5%), hematuria re-
quiring clot evacuation (1.4%), urinary retention requiring 
recatheterization (2.8%), urinary tract infection (4.3%), 
and prostatitis (1.4%) [27]. No urethral stricture, bladder 
neck contracture, or urinary incontinence was noted. Also, 
other studies showed that the retention rate requiring in-
tervention was 5% to 11% [30-35]. Both in a randomized tri-
al and in a prospective study comparing PVP and TURP, 
the rate of urethral stricture or bladder neck contracture 
was low and in the same range as for TURP and HoLEP 
[34,36]. It is suggested that at least 10 to 20 procedures 
should be performed on small prostates (＜40 ml) to avoid 
complications related to potential thermal damage before 
challenging large prostates [37]. Long-term follow-up also 
showed comparable results. After 5 years, complications 
were mild and rare, such as transient dysuria (6%), delayed 
hematuria (3%), and bladder neck contracture (2%); no in-
continence or newly developed impotence was reported. 
However, up to 26% of the sexually active men experienced 
retrograde ejaculation [31].
　The re-operation rate after traditional TURP due to re-
currence of BPH was known to be less than 12% [38]. 
According to 5-year follow-up data, only 19 of 246 patients 
were treated with repeat PVP because of reobstruction due 
to large glands, and 3 underwent transurethral incision of 
the bladder neck [32]. Table 2 summarizes the studies of 
the complications after PVP.
HOLMIUM LASER PROSTATECTOMY
1. General aspects of the holmium laser
The holmium:yttrium aluminium garnet (Ho:YAG) laser 
has been investigated as an alternative to the Nd:YAG la-
ser in the treatment of BPH because of its clear-cutting abil-
ities, immediate relief of symptoms, and good level of hemo-
stasis [39]. The Ho:YAG laser is a solid-state pulsed laser 
with a wavelength of 2,010 nm that is highly and rapidly 
absorbed by water, which constitutes 60% to 70% of the Korean J Urol 2010;51:737-744
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TABLE 2. Complication rates after PVP and HoLEP for BPH
Ref. No. of cases Age (yr) AUR UTI GHU Dysuria BNC Ureth. Str. Urinary inc. ED
PVP
HoLEP
20
24
29
34
35
27
45
48
49
50
51
60
61
  66
139
321
  64
  64
  70
  60
206
108
552
225
196
164
75
67.7±8.7
-
71.0±9.3
70.1±10.7
    67 (45-87)
69.2±8.4
70.5 (45-91)
71.5 (53-90)
73.7±7.9
73.7 (52-94)
67±11
72.1 (34-95)
7 (11%)
7 (5%)
-
 5 (7.8%)
1
 2 (2.8%)
-
16 (7.8%)
-
 8 (1.4%)
-
-
1
5 (8%)  
3 (2.2%)
-
  7 (10.9%)
-
3 (4.3%)
-
-
-
6 (1.1%)
4 (1.7%)
8 (4%)
3
-
12 (8.6%)
-
-
1
3 (4.3%)
-
5 (2.4%)
3 (2.8%)
-
8 (3.5%)
-
1
6 (9%) 
-
-
  7 (10.9%)
1
-
-
-
52 (9.4%)
-
21 (9.3%)
45 (23%)
-
1
2 (1.4%)
3
-
2
0
0
8 (3.9%)
1 (0.9%)
7 (1.3%)
1 (0.4%)
1 (0.5%)
-
-
1 (0.7%)
-
5 (7.8%)
-
0
-
5 (2.4%)
-
7 (1.3%)
3 (1.3%)
6 (3%) 
1
-
 9 (6.5%)
-
-
-
0
-
-
-
24 (4.2%)
16 (7.1%)
14 (7.1%)
5
-
0
-
0
-
-
-
-
-
-
-
-
-
PVP: photoselective vaporization of prostate, HoLEP: holmium laser enucleation of the prostate, BPH: benign prostatic hyperplasia,
Ref.: reference number, AUR: acute urinary retention, UTI: urinary tract infection, GHU: gross hematuria, BNC: bladder neck con-
tracture, Ureth. Str.: urethral stricture, Urinary inc.: urinary incontinence, ED: erectile dysfunction
prostate. The laser penetrates only 0.4 mm of the tissue, 
predominantly causing vaporization. Dissipating heat 
causes simultaneous coagulation, with minimal evidence 
of coagulative tissue necrosis. The physical properties of 
this laser make it suitable for use in different tissues, in-
cluding stones, due to the fact that water makes up a sig-
nificant component of most calculi. The first combined hol-
mium and Nd:YAG laser technique for prostatectomy was 
reported in 1995 by Chun et al [40] and Gilling and 
Fraundorfer [41]. The combination endoscopic laser abla-
tion of the prostate technique used the Ho:YAG laser, deliv-
ered by a side-firing fiber to create a channel, as an adjunct 
to the Nd:YAG laser to improve on the outcome of visual 
laser ablation of the prostate (VLAP). However, the hemo-
static properties of the Ho:YAG laser made the addition of 
the Nd:YAG laser largely redundant so that the improve-
ment in patient outcomes was minimal [42]. This finding 
led to the development of other techniques that exclusively 
use the Ho:YAG laser to imitate either a transurethral in-
cision of the prostate or TURP [43]. 
　After holmium laser ablation of the prostate (HoLAP) 
with the 60 W laser was first introduced in 1995 by Gilling 
et al [41], the high-powered (＞60 W) holmium laser was 
introduced and was shown to have the ideal physical pro-
perties to achieve accurate hemostasis in prostatic tissue 
with shorter operative times than before. To increase the 
efficacy of HoLAP, holmium laser resection of the prostate 
(HoLRP) and subsequently holmium laser enucleation of 
the prostate (HoLEP) were developed by Gilling and 
Fraundorfer [44]. The excellent hemostatic features of the 
holmium wavelength and the use of iso-osmotic saline sol-
ution as the irrigating fluid enable operations to be per-
formed on prostates of any size. In a series of reports, 
HoLEP has been demonstrated as a true endourologic al-
ternative to open prostatectomy in large prostates, and 
glands of larger than 300 g have been successfully enucleat-
ed [45-51]. A retrospective analysis of 225 patients with a 
mean prostate volume of 126 g (range, 80-351 g, median, 
111 g) demonstrated safe and effective results [51]. At 3 
years postoperatively, Qmax increased from 8.1 to 28.5 ml/s 
and PVR decreased from 325 to 46 ml. IPSS improved from 
18.7 to 3.7, and the QoL score improved from 3.7 to 0.7. 
　Nevertheless, uptake of the procedure has been limited 
partly because of a perception of a steep learning curve. 
Certainly, HoLEP is such a challenging technique that if 
a surgeon starts this procedure without supervision of ex-
perts, at least 50 patients are estimated to be sufficient to 
complete the initial learning curve [52]. Adequate mentor-
ing by an experienced urologist, however, can possibly 
shorten this learning curve [51]. 
2. Surgical technique
In HoLRP, the laser fiber cuts the prostatic lobes into pieces 
small enough to be evacuated through the resectoscope 
sheath, while dissecting the adenomatous tissue down to 
the prostatic capsule to create a TUR-like cavity. Later, the 
development of a trasurethral mechanical tissue morcella-
tor enabled a true enucleating technique: the HoLEP. 
Shelling out the adenoma, the laser fiber moves in exactly 
the same plane as the surgeon’s index finger does when per-
forming open prostatectomy. Gilling, who had first in-
troduced the holmium laser prostatectomy, elucidated his 
surgical technique as follows [53]. After preliminary cysto-
scopic evaluation, bilateral bladder neck incisions are 
made, extending from the ureteric orifices to the verumon-
tanum. These are deepened down to the level of the surgical 
capsule. Throughout the procedure, hemostasis is ob-
tained by using the defocused laser as each of the bleeding 
vessels is encountered. Then the median lobe is enucleated 
starting at the verumontanum. The incisions are con-
nected just above the verumontanum and the fibers con-
necting the median lobe to the capsule are divided. The lobe 
is disconnected at the bladder neck and placed in the blad-
der for later morcellation. The lateral lobes are each Korean J Urol 2010;51:737-744
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TABLE 3. Short-term and long-term results of holmium laser prostatectomy for BPH
Ref.
No. of 
cases
Mean age
(yr)
F/U
Mean
P vol.
QoL
score
Qmax PVR IPSS
Short-term
 
Long-term
54
56
57
58
55
59
200
  41
  30
  50
  60
607
68.0 (56-88)
66.26±6.55
71.7±1.1
67.68±9.8
69.2±8.4
-
3 yr
2 yr
2 yr
1 yr
5 yr
5 yr
Pre-op
Post-op
Pre-op
Post-op
Pre-op
Post-op
Pre-op
Post-op
Pre-op
Post-op
Pre-op
Post-op
53.5 (20-95)
-
113.27±35.33
-
77.8±5.6
28.4±1.8
62.6±14.8
-
114.6±21.6
-
68
27.2
-
-
4.07±0.93
  1.5±0.87
4.8±0.2
1.25±0.2
-
-
-
-
-
-
4.9 (0-11)
29.0±11.0
7.83±3.42
19.19±6.3
8.4±0.5
21.0±2.0
4.65±3.6
23.6±0.96
3.8±3.6
24.3±10.1
-
21.9
238 (50-1,000)
 8.4±16.0
-
-
-
-
103.0±174.1
＜20
280±273
10.6±24.4
-
-
22.1 (13-33)
2.7±3.2
20.11±5.84
7.9±6.2
26.0±1.1
6.1±1.0
24.9±3.9
5.4±0.28
22.1±3.3
3.0±3.2
-
-
Ref.: reference number, F/U: follow-up period, Mean P vol.: mean prostate volume, QoL: quality of life, Qmax: maximum urinary flow
rate, PVR: post void residual, IPSS: International Prostate Symptom Score, Pre-op: preoperation, Post-op: postoperation
enucleated in a retrograde fashion starting at the lower 
margin of the lobe at the apex. The bladder neck is incised 
at the 12 o’clock position and the incision extended laterally 
and distally to the level of the verumontanum. The lobe is 
then peeled down off the capsule and this is progressively 
extended distally over the length of the lobe. The upper and 
lower incisions are connected at the apex and the lateral 
lobe is enucleated in the capsular plane, working from the 
upper to the lower incisions. Once each of the lobes has been 
placed in the bladder, the prostatic fossa is further in-
spected for hemostasis. Prostate tissues in the bladder are 
fragmented and aspirated with the morcellator. Because 
of the excellent hemostatic ability of the holmium wave-
length and the use of iso-osmotic saline solution as the irri-
gating fluid, the transfusion rate is minimal, and TUR syn-
drome cannot happen. Studies on several hundreds of pa-
tients have demonstrated that HoLEP is a true endouro-
logic alternative to open prostatectomy in large prostates 
[45,46,48-51,54].
3. Results
　1) Short-term results: In each of the studies reported, 
HoLEP proved to be at least equal to both TURP and open 
prostatectomy in terms of relief from bladder outlet ob-
struction while providing all of the advantages of a mini-
mally invasive approach, including reduced morbidity, 
short catheterization time, and short hospital stay (Table 3) 
[54-57]. In a randomized study, Gupta et al prospectively 
compared HoLEP to TURP and to transurethral vapor-
esection of the prostate to compare HoLEP with other mini-
mally invasive ablative procedures [58]. Fifty patients 
were enrolled per arm, and blood loss, catheter and nursing 
time, and recatheterization were found to be significantly 
lower in the HoLEP group. 
　2) Long-term results: In a meta-analysis of data regard-
ing medium- and long-term urinary functional results, a 
total of 607 patients at a mean follow-up of 43.5 months 
were studied [58]. Functional results proved durable, with 
a mean Qmax of 21.9 ml/s and a mean reoperation rate of 
4.3% (range, 0-14.1%). A significant drop in serum PSA lev-
els from baseline (mean, 6.3 ng/dl to 1.63 ng/dl, post-
operatively) and in prostate volume at transrectal ultra-
sound (mean: from 68 ml to 27.2 ml, postoperatively) dem-
onstrated an effective anatomic relief of obstruction. So far 
as the surgeon achieves complete enucleation, especially 
at the apex, the durability of the results seems to persist. 
Cautious pre- and postoperative urodynmic assessment 
has confirmed that not only is the relief of obstruction with 
HoLEP superior, or at least equivalent to TURP, but that 
HoLEP is equivalent urodynamically to open prostatec-
tomy [55]. This result could also explain the relatively mild 
storage symptoms that are generally present in approx-
imately 30% of the patients at 1 month after surgery and 
that persist in 10% of patients at 3 months. These symp-
toms, however, are generally self-limiting and can be suc-
cessfully treated with medications such as non-steroidal 
anti-inflammatory drugs and anticholinergics. 
4. Complications
The pooled results of large case series revealed low compli-
cation rates of recatheterization (2.9%), urinary tract in-
fection (2.3%), urethral stricture/bladder-neck contracture 
(3.2%), and reoperation (2.8%) [45,48-51,60-62]. The peri-
operative mortality rate was 0.05% (1 of 1,847 patients). 
The operation time was significantly longer in the HoLEP 
group, but the perioperative morbidity was significantly 
lower. The blood loss was significantly less, and no blood 
transfusions were required. Shah et al reported a dis-
tribution of complications stratified evenly among all sizes 
of prostates analyzed, with a higher percentage (4.8%) of 
urethral strictures in prostates larger than 100 g [62].
OTHER LASERS
1. Thulium laser
In 2005, the thulium laser entered clinical practice and has Korean J Urol 2010;51:737-744
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become the most innovative and universally accepted laser 
equipment in urology after the introduction of the holmium 
laser [63]. The thulium laser is a high-performance laser 
using a similar 2,000 nm wavelength to the holmium laser 
but is delivered as a continuous wave (CW) rather than 
pulsed. Rapid absorption in water, short penetration depth, 
and incisional and hemostatic features are similar to those 
of the holmium laser, but the cutting is much smoother ow-
ing to the CW mode. The thulium laser is not only suitable 
for transurethral vaporization, bladder neck incision [64], 
or vaporesection [65,66], but is also suitable for vapoenu-
cleation of the prostate [67-69]. Mattioli et al reported data 
on 99 patients with small prostates (＜35 g), showing clin-
ically efficient vaporization in this group of patients [70]. 
The term vaporesection was introduced to point out the 
physical characteristics of the 2,000 nm CW Tm:TAG laser 
system with increased vaporization capacity [64]. With va-
poresection, tissue ablation is not only achieved by re-
section of TUR-like tissue chips, but also by simultaneous 
vaporization. Meanwhile, using the vapoenucleation tech-
nique, the prostatic tissue is enucleated in a three-lobe 
technique (median lobe, lateral lobes) as described in 
HoLEP, but again, the vaporizing capacities of the Tm: 
YAG laser improve the tissue ablation by concurrent 
vaporization. There is one randomized clinical trial com-
paring thulium with holmium laser enucleation [69]. In 
both groups, catheter removal was undertaken in an aver-
age of 18 hours with 95% of patients voiding successfully. 
Blood loss was minimal, and improvements in symptom 
scores, QoL scores, and peak urinary flow rates were sim-
ilar at 1 year postoperatively. No significant adverse 
events occurred. However, large series and long-term re-
sults are missing. 
2. Diode laser
Various types of diode lasers performing at wavelengths of 
940, 980, or 1,470 nm are available for diode-laser prosta-
tectomy. To date, only a few studies have reported clinical 
applications of these lasers with a maximum follow-up of 
1 year. Seitz et al reported that the high-power, 980 nm 
wavelength diode laser is a new promising alternative with 
a more rapid ablation rate and excellent hemostatic prop-
erties in ex vivo and in vivo animal models [71]. There are 
only few clinical pilot studies for the vaporization of the 
prostate using diode lasers. Two series used 980 nm diode 
lasers of different manufacturers [71,72] and one used a 
1,470 nm diode laser prototype [71]. Complication rates 
were low and the authors reported low or no perioperative 
bleeding. In a single nonrandomized clinical series com-
paring the diode laser treatment at 980 nm with the LBO 
laser [47], the authors described excellent hemostatic prop-
erties of the diode laser. Even though most of the patients 
continued anticoagulation treatment, only 2 patients (4%) 
needed irrigation postoperatively vs. 25 patients (40%) in 
the LBO laser arm. However, as a result of the increased 
tissue necrosis induced by the diode laser compared to the 
LBO laser, irritative symptoms as short-term complica-
tions such as prolonged dysuria or transient urge incon-
tinence occurred more often in the diode laser group. 
During the follow-up, retreatment rates and incontinence 
rates were also higher in the diode laser arm [47]. In a re-
cent comparative clinical study followed-up for 1 year using 
the GreenLight HPS laser (532 nm, 120 W) and the Diolas 
LFD diode laser (980 nm, 200 W), Chiang et al demon-
strated that the diode laser showed superior hemostatic 
properties compared with the GreenLight HPS laser [73]. 
Postoperative incontinence and postoperative irritative 
symptoms were more noticeable after diode laser pro-
statectomy. Higher incidence of dysuria with sloughing tis-
sues and epididymitis was noted after diode laser pro-
statectomy. Other complications were comparable for both 
procedures.
CONCLUSIONS
Until now, outcomes of laser prostatectomy for BPH are 
very encouraging. However, more clinical data are war-
ranted for laser prostatectomy to replace the status of 
TURP as a gold standard of surgical treatment for BPH.
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